The scientist’s investigation covers issues in Cancer research, Internal medicine, Lung cancer, Cancer and Breast cancer. His study in Cancer research is interdisciplinary in nature, drawing from both Immunohistochemistry, Reverse transcription polymerase chain reaction, Gene expression, DNA methylation and Carcinogenesis. Yoshitaka Fujii has included themes like Gastroenterology, Endocrinology, microRNA and Oncology in his Internal medicine study.
His Lung cancer study combines topics from a wide range of disciplines, such as Carcinoma, Surgery and Adenocarcinoma. As a part of the same scientific study, Yoshitaka Fujii usually deals with the Cancer, concentrating on Pathology and frequently concerns with Oncogene, Cell, Molecular medicine, CD8 and Esophageal disease. As a member of one scientific family, Yoshitaka Fujii mostly works in the field of Gefitinib, focusing on Insertion and, on occasion, Epidermal growth factor receptor.
Yoshitaka Fujii focuses on Cancer research, Internal medicine, Lung cancer, Pathology and Cancer. His studies examine the connections between Cancer research and genetics, as well as such issues in Gene expression, with regards to Messenger RNA, Metastasis and Molecular biology. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Endocrinology and Oncology.
His biological study spans a wide range of topics, including Surgery, Epidermal growth factor receptor, Carcinoma, Lung and Adenocarcinoma. His research in Epidermal growth factor receptor is mostly focused on Gefitinib. His studies in Pathology integrate themes in fields like Respiratory disease, Cell and Esophageal cancer.
His primary areas of study are Lung cancer, Cancer research, Surgery, Internal medicine and Cancer. His research in Lung cancer intersects with topics in Carcinoma, Oncogene, Survival rate and Adenocarcinoma. Yoshitaka Fujii has researched Cancer research in several fields, including Immunohistochemistry, Epidermal growth factor receptor, Mutation, KRAS and Metastasis.
His Surgery study integrates concerns from other disciplines, such as Idiopathic pulmonary fibrosis and Pneumonectomy. His work carried out in the field of Internal medicine brings together such families of science as Gastroenterology, Endocrinology, Single-nucleotide polymorphism and Oncology. His research integrates issues of Tyrosine-kinase inhibitor and Gefitinib in his study of Proportional hazards model.
His main research concerns Lung cancer, Cancer research, Adenocarcinoma, Pathology and Surgery. His Lung cancer study deals with the bigger picture of Internal medicine. His Cancer research study integrates concerns from other disciplines, such as Immunohistochemistry and Cancer.
His work deals with themes such as Breast cancer, Estrogen receptor and microRNA, which intersect with Immunohistochemistry. His research in Pathology intersects with topics in Myasthenia gravis and Chemotherapy. His Surgery research is multidisciplinary, incorporating perspectives in Exacerbation, Non small cell, Pneumonectomy and Usual interstitial pneumonia.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.
J. Guillermo Paez;Pasi A. Jänne;Pasi A. Jänne;Jeffrey C. Lee;Sean Tracy.
Characterizing the cancer genome in lung adenocarcinoma
Barbara A. Weir;Barbara A. Weir;Michele S. Woo;Gad Getz;Sven Perner;Sven Perner.
Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy.
Joji Kato;Yoshiyuki Kuwabara;Masami Mitani;Noriyuki Shinoda.
International Journal of Cancer (2001)
Extended thymectomy for myasthenia gravis patients: a 20-year review.
Akira Masaoka;Yosuke Yamakawa;Hiroshi Niwa;Ichiro Fukai.
The Annals of Thoracic Surgery (1996)
Involvement of Histone H1.2 in Apoptosis Induced by DNA Double-Strand Breaks
Akimitsu Konishi;Akimitsu Konishi;Shigeomi Shimizu;Junko Hirota;Toshifumi Takao.
miR-206 Expression is down-regulated in estrogen receptor alpha-positive human breast cancer.
Naoto Kondo;Tatsuya Toyama;Hiroshi Sugiura;Yoshitaka Fujii.
Cancer Research (2008)
Japanese Lung Cancer Registry Study of 11,663 Surgical Cases in 2004: Demographic and Prognosis Changes Over Decade
Noriyoshi Sawabata;Etsuo Miyaoka;Hisao Asamura;Yoichi Nakanishi.
Journal of Thoracic Oncology (2011)
microRNA expression profile in undifferentiated gastric cancer.
Takeyasu Katada;Hideyuki Ishiguro;Yoshiyuki Kuwabara;Masahiro Kimura.
International Journal of Oncology (1992)
Expression, Function, and Clinical Implications of the Estrogen Receptor β in Human Lung Cancers
Yoko Omoto;Yasuhito Kobayashi;Kazunori Nishida;Eiju Tsuchiya.
Biochemical and Biophysical Research Communications (2001)
Met gene copy number predicts the prognosis for completely resected non-small cell lung cancer.
Katsuhiro Okuda;Hidefumi Sasaki;Haruhiro Yukiue;Motoki Yano.
Cancer Science (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: